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Background
The epidemiology of Mycobacterium tuberculosis infection 
continues to change with an increasing number of cases 
identified among those born outside the United States.  LoBue 
and Mermin (2017), and Tsang and colleagues (2017) described 
the importance of identifying the presence of latent tuberculosis 
infection (LTBI) among the foreign-borne and the need to 
address both active and latent infection as part of a national 
public health strategy.   The United States (US) has historically 
resettled approximately 100,000 refugees and other entrants 
each year (ORR, 2016).  LTBI has been an area of concern at 
the University of Louisville Global Health Center (UL-GHC) due 
to the consistent rates of infection present among the resettling 
refugee population in Kentucky.  According to data collected 
by the UL-GHC, overall rates of LTBI among the refugee and 
immigrant population resettling in Kentucky was 9% versus 
5% among native-borne US citizens (Carrico, Goss, Wiemken, 
Bosson, Peyrani, Mattingly, et al., 2017). Reports demonstrating 
these rates of LTBI identified in refugees resettling in Kentucky 
over the course of the past five years can be found at http://
globalhealth.center/rhp/state.php. 
Using data available in the UL-GHC  Arriving Refugee 
Informatics SurVeillance and Epidemiology (ARIVE) 
database, a significant disconnect between LTBI treatment 
recommendations and completion was identified. During 
January 2013-December 2014, 45 (8%) refugees were diagnosed 
with LTBI.  All were referred to the local health department 
and provided appointments at dates and times agreeable to 
the refugee patient.  Of those, 25/45 (56%) kept the health 
department appointment and 20/45 (44%) agreed to initiation 
of treatment for LTBI.  Of those 20 who agreed to treatment, 
12/20 (60%) completed treatment.   That means of the 45 eligible 
for LTBI treatment, only 12/45 (27%) were treated resulting in 
a management gap of 73% (Figure 1). Barriers to treatment 
data previously gathered by UL-GHC researchers included:  1) 
lack of knowledge about LTBI and its importance to general 
health, 2) possibility of reactivation of the disease, 3) need for 
treatment despite lack of recognizable symptoms, 4) language 
differences among providers, 5) work schedule conflicts, and 
6) transportation to appointments as critical factors needing 
attention.   Further, refugees cited difficulties in accessing 
medication as a barrier to initiation as well as completion of the 
recommended LTBI treatment. These findings were consistent 
with treatment barrier information identified in the literature 
(Colson, Franks, Sondengam, Hirsch-Moverman, & El-Sadr, 
2010; Wieland, Weis, Yawn, Sullivan, Millington, Smith et 
al., 2012).  The poor rate of treatment completion combined 
with the many barriers to treatment acceptance prompted a 
complete review of existing LTBI management practices for 
this vulnerable population.  The result was implementation of a 
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Background: A review of newly arriving refugees referred to the local health department for 
latent tuberculosis infection (LTBI) treatment during 2013-2015 revealed a treatment gap of 73%, 
supporting the need to identify new approaches to treat vulnerable populations and mirrored results 
in the literature.
Objectives: 1) Describe an advanced practice registered nurse (APRN) led alternative approach to 
LTBI treatment in the refugee population; and 2) evaluate the impact of a 12-week regimen for LTBI 
on treatment acceptance, adherence and completion.
Methods: During the initial health screening visit, treatment options were provided for those identified 
with LTBI consisting of either a 12-week regimen requiring weekly directly observed therapy (DOT) 
or the traditional 9-month treatment.
Results: During March-December 2016, 50 refugees were referred and 24/50 were offered a 12-
week regimen of Rifapentine and Isoniazid, administered with DOT. 23 of the 24 or 96% completed 
the entire treatment course.
Conclusions: The new LTBI clinic process resulted in an increase in treatment acceptance and 
completion compared with the historic rate of 27%.
Implications for Nursing: APRN initiatives such as this can result in positive benefits to patients and 
communities while serving to advance the nursing profession in all practice settings
DOI: 10.18297/rgh/vol2/iss1/1
Submitted Date: July 03, 2018
Accepted Date: December 19, 2018
https://ir.library.louisville.edu/rgh/vol2/iss1
Affiliations:
1University of Louisville, Division of Infectious 
Diseases
2Northern Kentucky University, College of 
Health Professions, Department of Advanced 
Nursing Studies
3Harvard University
This original article is brought to you for free 
and open access by ThinkIR: The University 
of Louisville’s Institutional Repository. It has 
been accepted for inclusion in The Journal 
of Refugee & Global Health by an authorized 
editor of ThinkIR. For more information, 
please contact thinkir@louisville.edu.
Recommended Citation: Goss, Linda; 
Balcom, Dawn; Mutsch, Karen; Carrico, Ruth; 
and Bosson, Rahel (2019) “Treating Latent 
Tuberculosis Infection in Newly Arriving 
Refugees: An Advanced Practice Nurse 
Initiative at the University of Louisville Global 
Health Center,” Journal of Refugee & Global 
Health: Vol. 2 : Iss. 1 , Article 1. 
*Correspondence To: Linda Goss, DNP
Work Email: linda.goss@louisville.edu
Original Research
Copyright: © 2019 The author(s). This is an open access article distributed under 
the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), 
which permits unrestricted use, distribution, and reproduction in 
any medium, provided the original author and source are credited.
new clinic process led by an advanced practice registered nurse 
(APRN) expert in care for the refugee population and infectious 
diseases. 
The objectives of this project were: 1) describe this new LTBI 
clinic, and 2) share the results of its first six months of operation. 
Methods
This new approach to LTBI treatment provided in the UL-GHC 
refugee-centered medical home involved three core components 
and formed the basis for a pilot study assessing effectiveness.  A 
medical home is defined by the Agency for Healthcare Reseach 
and Quality (AHRQ) as a location for care that is organized in 
a way that services are accessible, organized and of sufficient 
quality (AHRQ 2012). The three core components included:  1) 
initiation of an LTBI clinic led by an advanced practice registered 
nurse (APRN), 2) use of global health navigators (GHN) as key 
support personnel in the LTBI care and treatment plan, and 3) 
use of a 12-week Isoniazid/Rifapentine (INH/RPT) treatment 
regimen with directly observed therapy (DOT) (Centers for 
Disease Control and Prevention [CDC], 2013).   DOT involves 
provision of medication to the recipient with visualization of 
medication self-administration. Therefore, DOT is a process 
that does not require a licensed healthcare worker as the patient 
is administering the medication to themselves. 
The LTBI clinic was conceptualized by a group of APRNs 
with expertise in refugee healthcare, infectious diseases, 
program development and evaluation in late 2015.  A lead 
APRN designed the clinic and workflow process with an 
emphasis on identification of specific competencies and skill 
sets needed by all members of the care team.   The UL-GHC 
had recently initiated a GHN program that engaged former 
refugees experienced in healthcare or health education.  These 
GHNs were brought into the LTBI clinic process as a means 
of promoting effective communication and culturally tailored 
care for the varied refugee populations targeted for LTBI 
treatment.   Recognizing the risks associated with incomplete 
LTBI treatment (e.g., development of drug resistance), the 
12-week INH/RPT treatment regimen promoted by CDC was 
chosen as the regimen of choice for the refugee population given 
their propensity for secondary migration and subsequent loss to 
follow-up (Greenwood & Warriner, 2011).  A new clinic led by an 
APRN, supported by other APRNs and GHNs was implemented. 
During the clinic development process, a number of tools and 
resources were developed that enabled an organized, efficient, 
and quality workflow such as DOT treatment log (Figure 2), 
education materials for patients and training materials for staff. 
All staff involved in the clinic were required to attend a specific 
training session where tuberculosis disease was reviewed 
and the ideal treatment regimens were discussed.  Individual 
refugee population needs were identified and targeted resources 
were developed including medication information sheets. 
Treatment logs and safe medication handling protocol were 
developed and included in subsequent training sessions.  Every 
person involved in the LTBI clinic was required to demonstrate 
competence in the areas of medication provision and handling, 
documentation, patient education, communication, and public 
health reporting.  Certificates of achievement were provided by 
the APRN to the clinic staff upon completion of the training and 
demonstration of competence.  
The new LTBI treatment approach began in early 2016 and 
data were collected after University of Louisville Institutional 
Review Board (IRB) approval and entered into ARIVE as part 
of standard of care documentation.  Data were collected in 
the LTBI clinic from  March-November 2016 and captured for 
analysis.  
Results 
The first six months (March-November 2016) of LTBI clinic 
operation are shown in Table 1. Twenty-four patients were 
provided with the INH/RPT regimen as standard of care. 
Of those, 23/24 (96%) completed the regimen within the 
suggested sixteen week time period, a significant improvement 
over the 27% completion rate using the previously described 
health department referral process.  One patient moved after 
completing the first four weeks and was lost to follow-up.  Six 
patients reported adverse events including nausea, diarrhea, 
fever, dizziness, and fatigue but none resulted in a regimen 
or treatment plan change.  There were 24/24 (100%) of the 
patients who received their medication through DOT and 8/24 
(33%) had at least one DOT episode provided in the home 
environment.  There were 24/24 (100%) who had at least one 
interaction with the GHN as part of the treatment process with 
23/24 (96%) having GHN involved in all DOT treatment doses. 
The results are demonstrated in Figure 3.   One of the 24 spoke 
English fluently and preferred that all interactions occur with 
the APRN leading the LTBI clinic program.  The new LTBI 
clinic process resulted in a treatment completion rate of 96%, 
and based on the results of the t-test, a statistically significant 
improvement over the previously used health department 
referral process (96% vs. 27%, p<.001) was identified.
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Figure 1 Latent Tuberculosis Infection (LTBI) Management Gap 
Figure 2.  Directly Observed Therapy Log (DOT): 12-Dose Isoniazid-Rifapentine LTBI Treatment 
 
Name:______________________________ DOB:_____________ Preferred Language:__________________  Sex: M  F   Weight__________lbs   Height__ft__inches  
Ethnicity: Hispanic  Non-Hispanic       Treatment Reason:   Refugee   Civil Surgeon   Travel   Employee Health   550 Clinic  Other_______________ 








*For events listed below, check if event/symptom occurs, otherwise leave blank. (The event may have occurred in the past, after a previous dose) 
Expected Date: /   / /  / /   / /   / /   / /   / /   / /   / /   / /   / /   / /   / 
Dose # 1 2 3 4 5 6 7 8 9 10 11 12 
Directly Observed Therapy (DOT) Received             
Side Effect check in box if present 
Visit Date: /   / /  / /   / /   / /   / /   / /   / /   / /   / /   / /   / /   / 
NO Adverse Reaction             
Loss of appetite             
Nausea or vomiting             
Yellow eyes or skin             
Diarrhea             
Rash/hives             
Fever or chills             
Sore muscles or joints             
Numbness or tingling             
Fatigue             
Dizziness/fainting             
Abdominal pain             
Other (describe in progress note)             
Tests-blood work (prn)             
Medical reconciliation             
Nutritional counseling             
Smoking cessation             
ETOH elimination             
Next Appointment /   / /  / /   / /   / /   / /   / /   / /   / /   / /   / /   / /   / 
Initials             
Rx stop or held             
Signatures Initials Signatures Date 
    
    
    
Final Disposition:  Date Treatment Completed: __/__/__  Date Treatment Stopped__/__/__ Reason for Stopping:  Lost of follow-up__ Moved__Other__Adverse Event__Pending Alternate Tx__ 
Current Medications:   
Medication Allergies:___________________________________________________________ NKDA_______ Food Allergies_______________________________________________________ 
_________________________________________ 
Figure 2 DOT Treatment Log
Discussion
The first six months of clinic operation identified a number of 
challenges including medication access, insurance verification, 
lapsing of insurance coverage, space constraints and other 
barriers previously identified such as transportation and work 
schedule conflicts.  This new clinic approach could not resolve 
some of these issues, such as those involving insurance, but the 
use of personnel able to effectively communicate with the refugee 
combined with an active outreach program and emphasis on use 
of the 12-week treatment regimen provided new opportunities 
for LTBI treatment options unable to be provided through the 
traditional public health systems.  
Limitations to this study involved the small sample size which 
limits the generalizability of the results.  
Clinical Implications and Conclusions
This is the first report of an APRN-led LTBI treatment approach 
in a refugee-centered medical home using a 12-week treatment 
regimen.  Aligning the clinic with the medical home enabled 
rapid access to other areas of expertise including primary 
care and specialty physicians and pharmacists. This level of 
collaborative practice served to maximize the use of multiple 
skill sets and enabled an effective inter-professional practice 
and education platform.  
The findings lend themselves to new research initiatives. For 
example, can our methods enhance LTBI management for the 
larger refugee population?  Can these approaches be generalized 
to the larger US population?  Therefore, further studies are 
needed to generate evidence on the effectiveness of interventions 
that are tailored to specific risk groups, consider the availability 
resources, and take into account the existing infrastructure of 
the healthcare system.
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Age, average (range) 38 ( 21-51) n= 24
Gender, male 18 (75%)
Country of Origin 
Burma/Myanmar   1 ( 4%)
Cuba 12 (50%)  
Democratic Republic of 
Congo
  3 (13%)
Eritrea   1 ( 4%)
Iraq   4 (17%)
Somalia   1 ( 4%)
Syria   2 (8%)
Preferred Language 
Spanish 12 (50%)
Arabic   6 (25%)
Swahili 2 ( 8%)
Chin   1 ( 4%)
English   1 ( 4%)
Kurdish   1 ( 4%)
Somali 1 ( 4%)
Treatment changes, n (%) 0 /24  (  0%)
Treatment completion n (%) 23/24 (96%)
Medication adverse events 6 /24   (25%)
Demographics
Treatment History
Table 1 DOT Treatment Log
Figure 3 Patients referred and treated in the LTBI clinic March-
November 2016
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